Correlation analysis of SLCO1B1 and APOE polymorphisms with atorvastatin lipid-lowering effect and toxic and side effects

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800018634

Enrollment

Unknown

Registered

2018-09-30

Start date

2019-01-01

Completion date

Unknown

Last updated

2018-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipemia

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults, the total cholesterol of fasting serum = 5.72mmol/L, or triglycerides = 1.70mmol/L, or low-density lipoprotein cholesterol = 3.12mmol/L, or high-density lipoprotein = 0.91mmol/L. No other lipid-lowering drugs were taken at the same time.

Exclusion criteria

Exclusion criteria: Abnormal liver and kidney function.

Design outcomes

Primary

Measure	Time frame
SLCO1B1 genotype;APOE genotype;	—

Countries

China

Contacts

Public ContactGuoyan Hu

The Fifth Affiliated Hospital of Guangzhou Medical University

hgychn@163.com+86 15002020600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026